High risk pregnancy > high risk pregnancy test > Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

High-risk pregnancy

High-risk Pregnancy: Non-Invasive Testing Reduces Potential Complications

High-risk pregnancy concerns women whose genetic profile entails higher chances of fetal chromosomal disorders including Down Syndrome and Patau Sydrome; it is therefore very important to undergo proper screening during the first trimester. As an alternative to invasive screening methods such as amniocentesis, EurofinsBiomnis offers genetic screening tests during pregnancythat present zero risk of fetal loss. This NIPT (non-invasive prenatal testing) procedure draws from a simple maternal blood sample, and offers an accuracy rate exceeding 99%. By choosing a non-invasive blood testing method during a high-risk pregnancy, it can be easily and safely determined whether risk of fetal chromosomal disorders is high or low, potentially avoiding amniocentesis procedures.

While Down Syndrome gets more attention in the media as a relatively common fetal disorder, it's equally important women seeking high-risk pregnancy tests to schedule Patau Syndrome blood testing, in order to rule out risks for the disorder also known as trisomy 13. Edward's Syndrome (trisomy 18) is also a risk that should be assessed.Eurofins Biomnis offers a simple screening kit for patients in need of screening for all three trisomies. Safe, reliable, and rapid, these high-risk pregnancy tests can be obtained starting in the tenth week of pregnancy. One easy test can offer expectant parents a great deal of reassurance, from early on.

To rule out common fetal abnormalities and disorders, scheduling a high-risk pregnancy screening test with a primary care physician or other healthcare provider offers patients a safe alternative to invasive tests, including for Edwards' syndrome (trisomy 18). The groundbreaking screening methods include Edwards' Syndrome blood testing kits that can be ordered to your physician's practice and carried out there, or at a Eurofins Biomnis partner laboratory. During your consultation, your healthcare provider will prescribe a NIPT and ask you to sign an informed consent form, which is mandatory for all genetic tests. This high-risk pregnancy screening test is quick: results are generally available after 7 working days.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%